Trials / Unknown
UnknownNCT03400735
Comparison of Cefdinir and Cefdinir/Clavulanic Acid Combination in Adults
Comparison of Cefdinir and Cefdinir/Clavulanic Acid Combination in Treatment of Acute Exacerbation of Chronic Bronchitis (AECB) and Community-acquired Pneumonia (CAP) in Adults
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- Sponsor
- Neutec Ar-Ge San ve Tic A.Ş · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
It is planned to compare the efficacy and safety of cefdinir and cefdinir/clavulanic acide treatments in acute exacerbation of chronic bronchitis (AECB) and community-acquired pneumoniae (CAP) patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| COMBINATION_PRODUCT | Cefdinir/clavulanic acide 300/125 mg film-coated tablets | Cefdinir is already an approved drug. In this study, developed cefdinir/clavulanic acide combination will be compared against to cefdinir alone. |
| DRUG | Cefdinir 300Mg Capsule | Cefdinir is used as comparator |
Timeline
- Start date
- 2017-11-01
- Primary completion
- 2018-04-01
- Completion
- 2018-08-01
- First posted
- 2018-01-17
- Last updated
- 2018-01-17
Locations
2 sites across 1 country: Turkey (Türkiye)
Source: ClinicalTrials.gov record NCT03400735. Inclusion in this directory is not an endorsement.